Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;103(1):e10-e12.
doi: 10.3324/haematol.2017.176347. Epub 2017 Oct 5.

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Konstantin Byrgazov  1 , Chantal Blanche Lucini  1 , Peter Valent  2 , Oliver Hantschel  3 , Thomas Lion  4
Affiliations

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Konstantin Byrgazov et al. Haematologica. 2018 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Competitive co-culture of BaF3 cells expressing BCR-ABL1Y253H/F359V and BCR-ABL1V299L/F359V. BaF3 cells expressing BCR-ABL1Y253H/F359V (black columns) and BCR-ABL1V299L/F359V (white columns) were mixed at a 1:9 ratio and incubated in the presence of 20 or 30 nM ponatinib. Clonal evolution was monitored by fluorescence of the co-expressed fluorescent proteins ZsGreen for BCR-ABL1Y253H/F359V and TdTomato for BCR-ABL1V299L/F359V. The results were confirmed by Sanger sequencing of the BCR-ABL1 TKD using gDNA and cDNA isolated and prepared at the indicated time points. The proportion of dead cells was calculated using Annexin/PI staining (striped columns). The indicated error bars are based on two biological and three technical replicates.
See this image and copyright information in PMC

References

    1. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412. - PMC - PubMed
    1. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428–442. - PMC - PubMed
    1. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562–2569. - PMC - PubMed
    1. Pritchard JR, Schmitt MW, Hodgson JG, et al. Analysis of the subclonal origins of compound mutations in patients with refractory Ph+ malignancies treated with ponatinib. Blood. 2016;128(22):1061.
    1. Deininger MW, Hodgson JG, Shah NP, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016;127(6):703–712. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources